Influenza and coronary artery disease: Exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarction

Reviews in Cardiovascular Medicine

Volumn 15, Issue 2, 2014, Pages 168-175

  Hebsur, Shrinivas ^a   Vakil, Erik ^a   Oetgen, William J ^b   Kumar, Princy N ^b   Lazarous, Daisy F ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Coronary artery disease; Inflammation; Influenza vaccine; Myocardial infarction

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; INCIDENCE; INFECTION PREVENTION; INFLAMMATION; INFLUENZA; INFLUENZA VACCINATION; MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); IMMUNOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; VACCINATION; VIROLOGY;

HUMANS; INFLAMMATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; MYOCARDIAL INFARCTION; PROGNOSIS; RISK FACTORS; VACCINATION;

EID: 84906326869     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0692     Document Type: Article

References (47)

1. Roger VL, Go AS, Lloyd-Jones DM, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-197.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
3. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol. 2009;333:43-82.
4. Influenza. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/nchs/fastats/flu.htm. Accessed April 18, 2014.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
6. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999;130:933-937.
7. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96-102.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
9. Vercellotti GM. Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium. Blood Cells. 1990;16;209-215.
10. Milnick CR, Fabricant CG, Fabrian J, Litrenta MM. Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol. 1979;96:673-706.
11. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
12. Nachtigal M, Legran A, Nagpal ML, et al. Transformation of rabbit vascular smooth muscle cells by transfection with the early region of SV40 DNA. Am J Pathol. 1990;136:297-306.
13. Van Lenten BJ, Hama SY, de Beer FC, et al. Antiinflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDK against LDK oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758-2767.
14. Naghavi M, Wyde P, Litovsky S, et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-defficient mice. Circulation. 2003;107:762-768.
15. Mehta RL, Rabb H, Shaw AD, et al. Cardiorenal syndrome type 5: clinical presentation, pathophysiology and management strategies from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:174-194.
16. Hendrix MG, Dormans PH, Kitslaar P, et al. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. Am J Pathol. 1989;134:1151-1157.
17. Hendrix MG, Daemen M, Bruggeman CA. Cytomegalovirus nucleic acid distribution within the human vascular tree. Am J Pathol. 1991;138:563-567.
18. Grayston JT, Kuo CC, Campbell LA, Benditt EP. Chlamydia pneumoniae, strain TWAR and atherosclerosis. Eur Heart J. 1993;14:66-71.
19. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;150:1785-1790.
20. Arcari CM, Gaydos CA, Nieto FJ, et al. Association between Chlamydia pneumoniae and acute myocardial infarction in young men in the United States military: the importance of timing of exposure measurement. Clin Infect Dis. 2005;40:1123-1130.
21. Etminan M, Carleton B, Delaney JA, Padwal R. Macrolide therapy for chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy. 2004;24:338-343.
22. Gurevich VS, Pleskov VM, Levaia MV, et al. Influenza virus infection in progressing atherosclerosis [in Russian]. Kardiologiia. 2002;42:21-24.
23. Gurevich V. Influenza, autoimmunity and atherogenesis. Autoimmun Rev. 2005;4:101-105.
24. Monto AS, Ullman BM. Acute respiratory illness in an American community. The Tecumseh study. JAMA. 1974;227:164-169.
25. Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol. 1998;31:1226-1233.
26. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618.
27. Meier CR, Jick SS, Derby LE, et al. Acute respiratorytract infections and risk of first time acute myocardial infarction. Lancet. 1998;351:1467-1471.
28. Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol. 1984;53:481-482.
29. Kuanprasert S, Apichartpikul N, Chuenkitmongkol S, et al. Evidence of influenza or influenza-like-illness preceding acute coronary syndrome. Southeast Asian J Trop Med Public Health. 2008;39:1040-1044.
30. Madjid, M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34, 892 patients. Eur Heart J. 2007;28:1205-1210.
31. Manfredini R, Manfredini F, Boari B, et al. Seasonal and weekly patterns of hospital admissions for nonfatal and fatal myocardial infarction. Am J Emerg Med. 2009;27:1097-1103.
32. FluNet Summary. World Health Organization Web site. http://www.who.int/ influenza/gisrs-laboratory/updates/summaryreport/en/. Accessed April 18, 2014.
33. Warren-Gash C, Bhaskaran K, Hawward A, et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis. 2011;203:1710-1718.
34. Siriwardena AN, Gwini SM, Coupland C. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ. 2010;182:1617-1623.
35. Jackson LA, Yu O, Heckbert SR, et al. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol. 2002;156:634-640.
36. Heffelfinger JD, Heckbert SR, Psaty BM, et al. Influenza vaccination and risk of incident myocardial infarction. Hum Vaccin.2006;2:161-166.
37. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002;105:2143-2147.
38. Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry. Registry Tex Heart Inst J. 2004;31:28-32.
39. Ciszewksi A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008;29:1350-1358.
40. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9:601-610.
41. Phrommintikul A, Kuanprasert S, Wongcharoen W, et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32:1730-1735.
42. Johnstone J, Loeb M, Teo KK, et al. Influenza vaccination and major adverse vascular evens in high-risk patients. Circulation. 2012;126:278-286.
43. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373-1381.
44. Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010;51:1007-1016.
45. Zimmerman RK, Santibanez TA, Janosky JE, etl al. What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and Veterans Affairs practices. Am J Med. 2003;114:31-38.
46. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655-1663.
47. Herrera GA, Iwane MK, Cortese M, et al. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vaccine. 2007;25:154-160.